Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Scandinavian Journal of Urology|September 8, 2020
Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world settingBörje Ljungberg, Pernilla Sundqvist, Per Lindblad, et al.
Proteomics|June 6, 2008
Detection of pancreatic cancer using antibody microarray-based serum protein profilingJohan Ingvarsson, Christer Wingren, Anders Carlsson, et al.
Scandinavian Journal of Urology|August 19, 2022
Surgical waiting times and all-cause mortality in patients with non-metastatic renal cell carcinomaAndreas Karlsson Rosenblad, Pernilla Sundqvist, Ulrika Harmenberg, et al.
Oncoimmunology|September 19, 2017
Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancerDhifaf Sarhan, Caroline Leijonhufvud, Shannon Murray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinomaBernard Escudier, Jan Roigas, Silke Gillessen, et al.
Oncoimmunology|March 24, 2025
Cellular and secretome profiling uncover immunological biomarkers in the prognosis of renal cell carcinoma patientsLe Tong, Veronika Kremer, Shi Yong Neo, et al.
Acta Oncologica (Stockholm, Sweden)|October 3, 2025
Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumabAlaa Kheir, Berglind Johannsdottir, Alexandra Grönn-Weiss, et al.
International Journal of Oncology|November 16, 2012
Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 GyJeff R Cortés-González, Enrique Castellanos, Katinka Sandberg, et al.
The Lancet. Oncology|January 9, 2013
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trialPirkko-Liisa Kellokumpu-Lehtinen, Ulrika Harmenberg, Timo Joensuu, et al.
European Urology|April 16, 2017
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025Bernard Escudier, Robert J Motzer, Padmanee Sharma, et al.
Pageof 4